PerkinElmer Supports PROXIDRUGS Consortium Aimed at Advancing Targeted Protein Degradation/PROTAC Drugs
22.4.2021 17:44:00 EEST | Business Wire | Press release
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced that it is serving as a provider and co-developer of assays, instrument solutions and expertise for the PROXIDRUGS Consortium which is zeroing in on research for proximity drugs or PROTACs (PROteolysis Targeting Chimeras). PROTACs are a new class of drugs that take advantage of the body’s own cell protein recycling system to fight disease by tapping into the 80% of disease-relevant proteins that are currently untargeted by today’s available therapeutics. Led by Goethe University in Frankfurt, Germany, the Consortium includes researchers from the Technical University of Darmstadt, the Fraunhofer Institute for Translational Medicine and Pharmacology, and global pharmaceutical companies based in Frankfurt’s Rhine-Main region.
The research project, starting October 2021, aims to streamline novel drug target validation by putting disease-relevant proteins in close proximity with key enzymes (such as E3 ligases) so that they can be marked for destruction and recycled by the cells’ natural shredding capabilities.
To help in these efforts, PerkinElmer will provide the consortium with no-wash AlphaLISA® and HTRF® immunoassay technologies and expertise in protein labeling as well as assay design; EnVision ® multimode plate readers; high content imaging technologies such as the Opera Phenix ® and Operetta CLS™ platforms; and data analysis and informatics tools like TIBCO Spotfire ® software. These PerkinElmer offerings will give PROXIDRUGS scientists a highly sensitive and accelerated discovery platform with rich data delivery and high throughput for both live and dead cell research.
Commenting on this groundbreaking research and collaboration, Alan Fletcher, SVP of Life Sciences at PerkinElmer said, “With only 20% of disease-relevant proteins currently being targeted by classical, small molecule drugs, new research approaches, such as PROTAC drug discovery, hold immense and exciting potential. We are delighted to be able to contribute our expertise and technologies to assist in the innovative work of the PROXIDRUGS Consortium as it seeks new ways to help unlock and tackle the vast majority of proteins behind widespread diseases such as cancer, neurological disorders, and cardiovascular, inflammatory and infectious conditions.”
The PROXIDRUGS consortium is led by Ivan Đikić of Goethe University Frankfurt, who also commented on the importance of forming alliances across organizations to help advance novel drug discovery and development: “Successful translation of biomedical research requires strong collaboration and convergence of industry and academic expertise. Our work with PerkinElmer within the PROXIDRUGS consortium is a good example of that. PerkinElmer’s expertise and innovation in assay development is of utmost importance and will help to create new insights for our discovery efforts.”
The PROXIDRUGS Consortium was recently selected for funding by the German Federal Ministry of Education and Research as part of a highly competitive “Clusters4Future” competition.
For more information please visit:
https://www.perkinelmer.com/category/drug-discovery-screening-solutions and https://aktuelles.uni-frankfurt.de/englisch/proxidrugs-project-led-by-goethe-university-included-in-clusters4future-programme/.
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the well-being and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210422005766/en/
Contact information
Jennifer McNeil
jennifer.mcneil@perkinelmer.com
+1 508.380.2902
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Biggest Predictor of Business Growth Is Behavior30.4.2026 10:00:00 EEST | Press release
IDEO, the global design and innovation company, today announced the IDEO Innovation Quotient (IDEO IQ), a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. Those with the highest IDEO IQ scores earned nearly $20 billion in profit last year—50% higher than average and three times more than those ranked at the bottom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429978890/en/ The IDEO Innovation Quotient (IDEO IQ) is a new report measuring how workplace behaviors drive business performance across 100 of the world’s largest companies. The IDEO IQ surveyed 266 leaders in product and innovation roles at 100 of the world’s largest companies across the Media & Technology, Healthcare, and Consumer Goods sectors. The report is the first of its kind to draw a direct line between how companies operate internally and their financial performance. Companies were surve
Suzano Sells 12.7 Million Tonnes of Pulp for the First Time in Its History30.4.2026 01:22:00 EEST | Press release
Suzano(B3: SUZB3 | NYSE: SUZ), the world’s largest pulp producer, announces its results for the first quarter of 2026 (1Q26), achieving a new all‑time record in pulp sales. Over the 12‑month period from April 2025 to March 2026, the company sold 12.7 million tonnes of pulp, the highest volume ever recorded in its history. During the same period, Suzano also sold 1.7 million tonnes of paper across the packaging, printing and writing, specialty, and tissue segments. This unprecedented sales level mainly reflects the increase in production capacity following the start‑up of the Ribas do Rio Pardo pulp mill in the state of Mato Grosso do Sul, as well as Suzano’s strong operational efficiency across its production lines and supply chains, serving customers in more than 100 countries worldwide. In the first quarter of 2026, Suzano sold a total of 3.2 million tonnes, comprising 2.8 million tonnes of pulp and 378 thousand tonnes of paper. Net revenue amounted to BRL 11.0 billion, while adjuste
The Estée Lauder Companies Announces Minority Investment in Luxury Clinical Skin Care Brand 111SKIN29.4.2026 23:30:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE:EL) today announced a minority investment in 111SKIN, a luxury clinical skin care brand founded by renowned plastic and reconstructive surgeon Dr. Yannis Alexandrides. Terms of the investment were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429495879/en/ 111SKIN's Reparative Collection Founded in 2012, 111SKIN was originally developed by Dr. Alexandrides to accelerate his patients’ healing time following procedures. At the heart of the brand is its innovative NAC Y2™, a pioneering complex designed to support skin repair and maintain a healthy, radiant and resilient complexion. Building on the foundation of this clinical expertise, 111SKIN has developed a portfolio of more than 30 products, anchored by its Black Diamond and Reparative collections and priced from $50 to $1,000. “Skin care is entering a new phase, shaped by the convergence of procedures, longevity and b
IFF Declares Dividend for Second Quarter 202629.4.2026 23:25:00 EEST | Press release
IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2026 to shareholders of record as of June 18, 2026. Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Learn more at iff.com, LinkedIn, Instagram and Facebook. © 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved. View source version on businesswire.com: https://www.businesswire.com/news/home/20260429658065/en/
Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn29.4.2026 21:25:00 EEST | Press release
Estithmar Holding Q.P.S.C. announced its financial results for the first quarter of 2026, reporting a net profit of QAR 333 million, marking a significant 97% increase compared to the same period last year. The results underscore the strength of the Company’s operating model and the successful execution of its expansion strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429718889/en/ Estithmar Holding Reports 97% Surge YoY in Q1 2026 in Net Profit to QAR 333 Mn (Photo: AETOSWire) The company recorded revenues of QAR 1.455 billion, up from QAR 1.309 billion in Q1 2025. Gross profit rose to QAR 561 million compared to QAR 416 million, representing a year-on-year increase of 35%. EBITDA grew by 73% to reach QAR 473 million, while earnings per share increased by 90% to QAR 0.089. These results reflect comprehensive growth across all key financial indicators, supported by a clear investment vision and the Company’s abili
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom